Metharbital, also known as Methylphenobarbital, is a synthetic barbiturate derivative with anticonvulsant and sedative-hypnotic properties. It is structurally related to phenobarbital and has historically been used in pharmaceutical preparations for the management of seizure disorders.
Metharbital acts primarily through modulation of GABAergic neurotransmission, producing central nervous system depressant and anticonvulsant effects.
Metharbital has the molecular formula C13H16N2O3 and a molecular weight of approximately 248.28 g/mol. Its CAS Number is 50-11-3.
It is a synthetic barbiturate compound belonging to the pyrimidine-2,4,6-trione family. Metharbital is generally supplied as a pharmaceutical-grade active ingredient for qualified pharmaceutical applications.
Metharbital is a barbiturate that enhances inhibitory neurotransmission mediated by the GABA-A receptor system. Increased GABAergic activity reduces neuronal excitability and contributes to its anticonvulsant and central nervous system depressant effects.
Metharbital has historically been associated with:
Its current availability and approved pharmaceutical applications may vary by country and regulatory jurisdiction.
Metharbital API can be evaluated using validated analytical procedures for identification, assay, related substances, water content, residue on ignition, residual solvents and elemental impurities, as applicable.
HPLC, infrared spectroscopy and other validated analytical methods may be used for identity, assay and impurity profiling. Final acceptance criteria should follow the manufacturer's validated drug-substance specification and current Certificate of Analysis.
Metharbital should be stored in a tightly closed pharmaceutical-grade container in a cool, dry environment and protected from excessive heat, moisture and direct light.
Because metharbital is a pharmacologically active barbiturate, handling and storage should comply with applicable pharmaceutical and controlled-substance requirements.
Metharbital API may be supplied for qualified pharmaceutical manufacturing, formulation development, analytical and research applications, subject to applicable quality, regulatory and controlled-substance requirements.
Metharbital is a specialized barbiturate API associated with anticonvulsant pharmaceutical applications. Product specifications, Certificate of Analysis, analytical documentation, packaging information and regulatory documentation can be provided according to applicable requirements.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 1.0% |
| Individual Impurity | NMT 1.0% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |